Paclitaxel /sqm IV

Phase 2Small molecule

GGruppo Oncologico Italiano di Ricerca Clinica

Paclitaxel /sqm IV is one of 67 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PORTRAZZA

Eli Lilly

Preclinical

8 2

Ofev

Boehringer Ingelheim

Preclinical

7 3

Paclitaxel /sqm IV

GGruppo Oncologico Italiano di Ricerca Clinica

Phase 2

1 4

Remeron

OOrganon and Co

Preclinical

1 5

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 6

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

1 10

Vidaza

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07418931

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer

Not yet recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT07418931·108 enrolled

Pancreatic Cancer1 trial

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 1/2·NCT02109341·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Paclitaxel /sqm IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel /sqm IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel /sqm IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gruppo Oncologico Italiano di Ricerca Clinica company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGruppo Oncologico Italiano di Ricerca Clinica

Paclitaxel /sqm IV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News